Management of elderly patients with chronic lymphocytic leukemia in the era of targeted therapies
- 1 September 2015
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 27 (5) , 365-370
Abstract
International audienceChronic lymphocytic leukemia (CLL) is frequently diagnosed after 71 years, though median age in published clinical trials with standard chemoimmunotherapy regimens in frontline or relapse setting is mostly below 70 years (58-71 years). Development of oral, less toxic and thus more affordable targeted therapies offers new therapeutic options in those patients deemed unfit for chemotherapy.Recent findingsThis review will discuss results of these new agents in the therapy of elderly patients. Apart from discussing the impact of chronological age, creatinine clearance and cumulative illness rating scale scores in the clinical outcomes, we will also discuss how individualized treatment decision-making should include more precise geriatric assessment tools to thoroughly assess life expectancy, anticipate tolerability, to avoid deleterious stress precipitating prefrail patients into definitive loss of capacity, with dramatic social and economic costs.SummaryIn the era of new targeted agents to fight cancers, we propose concepts to help us understand how elderly dedicated trial designs and geriatric assessment tools (apart from the evaluation of CLL biological risk factors) will undoubtedly revolutionize therapeutic approaches in everyday practice CLL patientsKeywords
This publication has 21 references indexed in Scilit:
- Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab into Clinical PracticeClinical Lymphoma Myeloma and Leukemia, 2015
- Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trialThe Lancet, 2015
- Accumulation of adverse prognostic markers worsens prognosis in chronic lymphocytic leukaemiaBritish Journal of Haematology, 2014
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting ConditionsNew England Journal of Medicine, 2014
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2014
- Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trialsHaematologica, 2014
- Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trialThe Lancet Oncology, 2014
- Treatment of older patients with chronic lymphocytic leukemia: key questions and current answersHematology-American Society Hematology Education Program, 2013
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2013
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialThe Lancet, 2010